Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma

Ipsita Pal, Anuradha Illendula, Andrea Joyner, John Sanil Manavalan, Tess M. Deddens, Ariana Sabzevari, Deepthi P. Damera, Samir Zuberi, Enrica Marchi, Todd E. Fox, Marya E. Dunlap-Brown, Kallesh D. Jayappa, Jihane Khalife, Jeffrey W. Craig, Thomas P. Loughran, Jr., David J. Feith, Owen A. O’Connor

Blood (2025) 146 (23): 2794–2807.

https://doi.org/10.1182/blood.2024027997

Published: 2025

Includes: Supplemental data

Journal Articles

Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort

Blood (2025) 146 (Supplement 1): 1054.

https://doi.org/10.1182/blood-2025-1054

Published: 2025

Journal Articles

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis

Blood (2025) 146 (Supplement 1): 893.

https://doi.org/10.1182/blood-2025-893

Published: 2025

Journal Articles

Targeting the methylome in T-LGL leukemia: Pre-clinical analysis and Results of a Phase I trial with oral 5-azacytidine

Jonathan Brammer, Zachary Braunstein, Patrick Stevens, Zachary Hutchins, Giulia Calabretto, Soprina Guarneri, Eric McLaughlin, Amy Boles, John Reneau, Walter Hanel, Enrica Marchi, Maciej Pietrzak, Anjali Mishra

Blood (2025) 146 (Supplement 1): 890.

https://doi.org/10.1182/blood-2025-890

Published: 2025

Journal Articles

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Mark Sorial, Kenechukwu Aniagboso, Emily Buttermore, Matthew Lei, Ellen Kendall, Kristiana Nasto, Min Jung Koh, Jessy Xinyi Han, Leora Boussi, Luis Malpica, Brady Beltran, Laura Korin, German Stemmelin, Carlos Chiattone, Denisse Castro, Fabiola Valvert, Jule Vasquez, Henry Quintero, Macarena Roa, Alfredo Quiroz, Marialejandra Torres Viera, Luis Mario Villela Martinez, Ana Oliver, Cesar Augusto Samanez Figari, Edith Julia, Vincent Camus, Catherine Thieblemont, Philippe Gaulard, Laurence de Leval, Franck Morschhauser, Emmanuel Bachy, Omar Elghawy, Stefan Barta, Jack Malespini, Kusha Chopra, Caroline MacVicar, Sean McCabe, Luke Peng, Shambhavi Singh, Makoto Iwasaki, Ijeoma Eche-Ugwu, Judith Gabler, Maria J Fernandez, Alexander Disciullo, Josie Ford, Alexandra Lenart, Emmanuel Nwodo, Jeffrey Barnes, Min Ji Koh, Eliana Miranda, Robert Stuver, Mwanasha Merrill, Eric Jacobsen, Martina Manni, Monica Civallero, Tetiana Skrypets, Athina Lymboussaki, Massimo Federico, Yu Ri Kim, Jin Seok Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Manju Sengar, Hasmukh Jain, Carrie Van Der Weyden, H. Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won-Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Maria Elena Cabrera, Govind Bhagat, Helen Ma, Ahmed Sawas, Dhruv Mistry, Khyati Kariya, Forum Bhanushali, Maya Krishnan, Erica Lee, Owen O'Conner, Enrica Marchi, Devavrat Shah, Changyu Shen, Salvia Jain

Blood (2025) 146 (Supplement 1): 889.

https://doi.org/10.1182/blood-2025-889

Published: 2025

Journal Articles

Final results from the embolden trial: pembrolizumab in combination with decitabine and pralatrexate in heavily pretreated patients with peripheral and cutaneous T-cell lymphoma

Nathan Roberts, John Lister, N. Nora Bennani, Salvia Jain, Tammy Battaglia, Marian Abdelmalek, Bethany Horton, Emily Ayers, Craig Portell, Thomas Cropley, Prem Batchala, Ipsita Pal, John Manavalan, Owen O'Conner, Enrica Marchi

Blood (2025) 146 (Supplement 1): 5417.

https://doi.org/10.1182/blood-2025-5417

Published: 2025

Journal Articles

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Blood (2025) 146 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2025-3646

Published: 2025

Journal Articles

Initial clinical data from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with large granular lymphocytic leukemia

Enrica Marchi, Tapan Kadia, Ryotaro Nakamura, Christina Poh, Costas Yannakou, Mitul Gandhi, Jasmine Zain, Steven Horwitz, Jenna Reed, Jennifer Richardson, Ruoshi Shi, Kimberley Dilley, Wan-Jen Hong, Nenad Tomasevic, Natali Pflug, Thierry Lamy, Marco Herling, Jonathan Brammer, Thomas Loughran

Blood (2025) 146 (Supplement 1): 777.

https://doi.org/10.1182/blood-2025-777

Published: 2025

Journal Articles

Cytotoxic lymphoma assessment response (CLyAR): A harmonized, compartment-based consensus response assessment framework for cytotoxic T-cell lymphomas

Blood (2025) 146 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2025-1872

Published: 2025

Journal Articles

Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Blood (2024) 144 (Supplement 1): 982.

https://doi.org/10.1182/blood-2024-194242

Published: 2024

Journal Articles

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Jasmine Zain, Swaminathan P Iyer, Enrica Marchi, Mitul Gandhi, Youn H. Kim, Michael S. Khodadoust, Jonathan E. Brammer, Christina Poh, Pierluigi Porcu, Kimberley Dilley, Matthias Will, Andrea Kantor, Cathrine Leonowens, Nenad Tomasevic, H. Miles Prince, Steven Horwitz

Blood (2024) 144 (Supplement 1): 980.

https://doi.org/10.1182/blood-2024-206053

Published: 2024

Journal Articles

Exploring the Tumor Microenvironments of Follicular Helper T-Cell Lymphomas of Angioimmunoblastic-Type and Follicular-Type Using the Geomx® Digital Spatial Profiler

Jeffrey W Craig, Sahil Chaudhary, Patcharin Pramoonjago, Ipsita Pal, Nathan Roberts, Enrica Marchi

Blood (2024) 144 (Supplement 1): 6243.

https://doi.org/10.1182/blood-2024-201722

Published: 2024

Journal Articles

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

Blood (2024) 144 (Supplement 1): 4433.

https://doi.org/10.1182/blood-2024-210301

Published: 2024

Journal Articles

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Min Jung Koh, Jessy Xinyi Han, Leora Boussi, Mark N Sorial, Sean M McCabe, Luke Peng, Shambhavi Singh, Ijeoma Julie Eche-Ugwu, Judith Gabler, Maria J. J. Fernandez Turizo, Caroline MacVicar, Aditya Garg, Alexander Disciullo, Kusha Chopra, Alexandra W Lenart, Emmanuel Nwodo, Jeffrey A. Barnes, Min Ji Koh, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven Horwitz, Mwanasha H. Merrill, Eric D. Jacobsen, Jin Seok Kim, Yu Ri Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, Saswata Saha, Hasmukh Jain, Manju Sengar, Carrie Van Der Weyden, H. Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M. Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Josie G Ford, Martina Manni, Monica Civallero, Tetiana Skrypets, Massimo Federico, Maria Elena Cabrera, Amy Ku, Govind Bhagat, Helen Ma, Ahmed Sawas, Khyati Kariya, Makoto Iwasaki, Forum Bhanushali, Owen A. O'Connor, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood (2024) 144 (Supplement 1): 465.

https://doi.org/10.1182/blood-2024-201874

Published: 2024

Journal Articles

Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL)

Enrica Marchi, Jeffrey W. Craig, Matko Kalac

Blood (2024) 144 (18): 1898–1909.

https://doi.org/10.1182/blood.2023021788

Published: 2024

Includes: Supplemental data

Journal Articles

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Blood (2023) 142 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2023-181130

Published: 2023

Journal Articles

Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Blood (2023) 142 (Supplement 1): 1703.

https://doi.org/10.1182/blood-2023-185881

Published: 2023

Journal Articles

Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study

Mark N Sorial, Min Jung Koh, Leora Boussi, Jessy Xinyi Han, Luke Peng, Ijeoma Julie Eche-Ugwu, Rui Duan, Matthew M. Lei, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven M. Horwitz, Maria J. Fernandez Turizo, Sean McCabe, Mwanasha Hamuza Merrill, Eric Jacobsen, Jin Seok Kim, Yu Ri Kim, Jae Yong Cho, Hasmukh Jain, Manju Sengar, Thomas Eipe, Tanuja Shet, Shambhavi Singh, Uvette Lou, Hesham Raghib, Judith Gabler, Min Ji Koh, Carrie Van Der Weyden, Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M. Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Josie Ford, Martina Manni, Massimo Federico, Owen A. O'Connor, Maria Elena Cabrera, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood (2023) 142 (Supplement 1): 3080.

https://doi.org/10.1182/blood-2023-182341

Published: 2023

Journal Articles

PTCL and ICIs: a matter of time and subtype

Enrica Marchi

Blood (2023) 142 (7): 613–614.

https://doi.org/10.1182/blood.2023021304

Published: 2023

Journal Articles

The Novel Nano-Formulation of the HDAC Inhibitor, Romidepsin, for the Treatment of Relapsed, Refractory Peripheral T-Cell Lymphoma

Ipsita Pal, Anuradha Illendula, John Sanil Manavalan, Todd P Fox, Owen A. O'Connor, Thomas P. Loughran, Jr., Mark Kester, David J Feith, Enrica Marchi

Blood (2022) 140 (Supplement 1): 8848–8849.

https://doi.org/10.1182/blood-2022-167628

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma

Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis

Targeting the methylome in T-LGL leukemia: Pre-clinical analysis and Results of a Phase I trial with oral 5-azacytidine

Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium

Final results from the embolden trial: pembrolizumab in combination with decitabine and pralatrexate in heavily pretreated patients with peripheral and cutaneous T-cell lymphoma

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Initial clinical data from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with large granular lymphocytic leukemia

Cytotoxic lymphoma assessment response (CLyAR): A harmonized, compartment-based consensus response assessment framework for cytotoxic T-cell lymphomas

Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Exploring the Tumor Microenvironments of Follicular Helper T-Cell Lymphomas of Angioimmunoblastic-Type and Follicular-Type Using the Geomx® Digital Spatial Profiler

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL)

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study

PTCL and ICIs: a matter of time and subtype

The Novel Nano-Formulation of the HDAC Inhibitor, Romidepsin, for the Treatment of Relapsed, Refractory Peripheral T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only